Stole this from CEM, why Nolva should be used against progetserone/prolactin gyno

[RoadHouse]

Tamoxifen inhibits prolactin signal transduction in ER - NOG-8 mammary epithelial cells.

Das R, Vonderhaar BK.

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892-1402, USA.barbarav@helix.nih.gov

Tamoxifen (TAM), an antiestrogen, also acts as an antilactogen in mammary cells. In the present study we analyze the effect of TAM on the signal transduction pathway for prolactin (Prl). TAM bound specifically to NOG-8, an estrogen receptor-negative mammary cell line. Within 5 min of Prl treatment, raf-1, MEK and MAP kinase were induced 2-3-fold over the control level. TAM completely inhibited this Prl-induced activation of kinases as well as Prl binding and cell growth. These results indicate the potential role of TAM as an antilactogen in Prl responsive systems.

(3)Fertil Steril 1995 Oct;64(4):818-24 Related Articles, Links


Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia.

Adamopoulos DA, Nicopoulou S, Kapolla N, Vassilopoulos P, Karamertzanis M, Kontogeorgos L.

Endocrine Department, Elena's Hospital, Athens, Greece.

OBJECTIVE: To evaluate the effects of T undecanoate given as a supplementary treatment with tamoxifen citrate (TAM) or hMG on pituitary and Leydig cell function in men with idiopathic oligozoospermia. DESIGN: A total of 48 normogonadotropic men with idiopathic oligozoospermia were allocated in to six groups (n = 8 per group) treated with placebo, 40 mg T undecanoate three times per day, 10 mg TAM two times per day, T undecanoate and TAM, 75 IU/d hMG, and T undecanoate and hMG. All groups were evaluated with standard GnRH, thyrotropin-releasing hormone, and hCG tests before and on the final day of 3 months on treatment with measurements of FSH, LH, thyroid-stimulating hormone (TSH), PRL, T, E2, 17-hydroxyprogesterone, sex hormone-binding globulin, and seminal analyses (at least twice each time). RESULTS: Basal and stimulated concentrations and incremental FSH and LH values showed no differences among TAM or hMG and TAM + T undecanoate or hMG + T undecanoate treated groups. Basal, stimulated, and incremental values for TSH and PRL were elevated markedly during treatment in most groups in comparison to placebo. Basal, stimulated, and incremental T and E2 values were similar in active treatment groups except that higher T concentration was found in TAM + T undecanoate as compared with T undecanoate only treated men. Finally, significant improvements were noted in important seminal parameters and particularly in the functional sperm fraction of the TAM + T undecanoate group as compared with single treatment with TAM. CONCLUSION: These results indicate that T undecanoate in combination with TAM or hMG not only had no adverse effects on pituitary and Leydig cell activity but also seemed to improve important seminal parameters and signify that androgens may be tried as a supplementary treatment to conventional regimes in idiopathic oligozoospermia.

 

[RoadHouse]

Antiestrogenic properties of raloxifene.

Draper MW, Flowers DE, Neild JA, Huster WJ, Zerbe RL.

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.

This 21-day, open-label study evaluated the effects of raloxifene and tamoxifen on estrogen-induced changes in serum levels of anterior pituitary hormones (prolactin, luteinizing hormone, and follicle-stimulating hormone), sex steroids (testosterone, estradiol), and binding globulins [thyroid binding globulin (T3 resin uptake), transcortin, sex steroid binding globulin]. Seventeen healthy male volunteers completed the study after being randomized to one of three treatments: raloxifene, tamoxifen, or placebo. Six subjects received raloxifene (200 mg daily) for 10 days, 6 subjects received tamoxifen [20 mg twice a day (b.i.d.)] for 10 days, and 5 subjects received placebo for 10 days. All subjects received ethinyl estradiol (20 micrograms b.i.d.) for 7 days starting 3 days after initiation of study drug or placebo treatment. Results of the primary analysis of this study indicate that for six of the seven analyzable parameters of estrogen action (excluding luteinizing hormone) raloxifene blunted the estrogen response; this effect was significant only for T3 resin uptake. Tamoxifen administration significantly blunted or reversed the estrogen effect in all six of these parameters. Raloxifene, an effective antiestrogen in animal models, is also antiestrogenic in humans.

 

[RoadHouse]

Nandi's commentary:
Anyway, when ethinyl estradiol was given, prolactin increased by 2.96 ng/ml above baseline in the placebo group. Tamoxifen completely reversed this leading to a drop of 1.29 ng/ml below baseline. Raloxifene only blunted the increase: after raloxifene administration, prolactin remained elevated by 0.85 ng/ml.

So for those people worried about the (IMO non-existent) prolactin induced gyno, tamoxifen looks like it would be an effective treatment. Another reason to forget the foolish use of bromocriptine to treat gyno and just stick with the tried and true Nolvadex.

 

[hhajdo]

Yes, if PRL increase is caused by elevated estrogen you can use tamox to inhibit it....


Acta Endocrinol (Copenh) 1984 Feb;105(2):167-72

Testosterone-induced hyperprolactinaemia in a patient with a disturbance of hypothalamo-pituitary regulation.

Nicoletti I, Filipponi P, Fedeli L, Ambrosi F, Gregorini G, Santeusanio F.

A case of a patient with hypopituitarism due to a disturbance of hypothalamo-pituitary regulation is presented, who developed high-grade hyperprolactinaemia after the initiation of substitutive therapy with testosterone esthers.The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. The oestrogen effect in raising Prl release was not attributable to a reduction in the dopamine inhibition of Prl-secreting cells, as the dopamine-antagonist domperidone failed to increase Prl serum levels in the same patient. This suggests that, in man, the oestrogen effect in enhancing Prl release is mainly enacted directly on the pituitary lactotrophs rather than exerted through a reduction in the hypothalamic dopamine ..

 

[hhajdo]

Tamoxifen inhibits lactation:

Eur J Obstet Gynecol Reprod Biol 1975;4(5):167-9 Related Articles, Links


Suppression of lactation by an antiestrogen, tamoxifen.

Shaaban MM.

The efficacy of a new antiestrogen, tamoxifen, in the suppression of lactation was tested in a placebo-controlled double-blind trial in 150 puerperal women. It proved to be very effective in preventing milk secretion and breast engorgement when its administration was commenced within two hours after delivery. No side effects were observed. Two dosage schedules were compared.



Br J Obstet Gynaecol 1978 Feb;85(2):134-7 Related Articles, Links


Inhibition of lactation and inhibition of prolactin release after mechanical breast stimulation in puerperal women given tamoxifen or placebo.

Masala A, Delitala G, Lo Dico G, Stoppelli I, Alagna S, Devilla L.

Tamoxifen was given orally to 60 puerperal women to inhibit lactation. Twenty control puerperal women were given placebo. Fifteen women receiving tamoxifen and 15 women receiving placebo were studied before, during and after the use of a breast pump under basal conditions and after five days of treatment. Tamoxifen was effective in inhibiting lactation; no rebound phenomena were observed. Its administration was free from side effects. This drug was capable of preventing the prolactin release induced by mechanical breast stimulation. Placebo failed to inhibit lactation and had no effect on prolactin release induced by the use of a breast pump

 

[RoadHouse]

So in your opinion hhjado, is bromo pretty much useless except for fat burning or sexual purpsoses?

 

[Rj*]

so, just use ~ 20mg nolva/ day

 

[hhajdo]

So in your opinion hhjado, is bromo pretty much useless except for fat burning or sexual purpsoses?

I wouldn't recommend it for fat loss or sex drive.
The improvement in sex drive is significant in hyperprolactinemic men, not normal ...
Some people who used it experienced no improvement...


Nandi12 explained the possible sides in his article:

Bromocriptine for Weight Loss

 

[SWALE]

Let's keep in mind, as we extrapolate these studies from normal physiological ranges to Anabolic Androgenic Steroids (AAS) dosages, that the hormonal milieu is much different for us.